...
EXELLARGE

Exelixis, Inc.

HealthcareBiotechnology
$44.06
$0.00(-0.50%)
52W$32.38
$49.62
FinancialsValuationvs RVMD
Updated Mar 2, 12:00 AM
RSI53
RS Rating57/99
Beta0.63
Volatility43%
F-Score7/9
Mkt Cap$11.8B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Exelixis, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 57), indicating performance broadly in line with the market. Earnings growth of 75% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.

Relative Strength
57
out of 99
Average
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
0.63
vs S&P 500
DEFENSIVE
52W Position
68%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$43.99
50 SMA > 100 SMA$42.37
100 SMA > 150 SMA$41.12
150 SMA > 200 SMA$41.74

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$43.56+1.15%ABOVE
50 SMA$43.99+0.15%ABOVE
100 SMA$42.37+4.00%ABOVE
150 SMA$41.12+7.16%ABOVE
200 SMA$41.74+5.55%ABOVE

Price Performance

1D-0.5%
1W+0.1%
1M+3.3%
3M-0.2%
6M+16.3%
YTD+1.1%
1Y+13.9%
3Y+37.1%
52-Week Trading Range68% from low
$44.06
52W Low$32.38
52W High$49.62

Technical Indicators

RSI (14)NEUTRAL
53.1
305070
VCP ScoreWARM
8/10
Base depth: 15.2%

Risk Profile

Beta
0.63
52W Vol
43%
ATR
$1.26
Max DD (1Y)
-25%

Volume Analysis

Today
44
50D Avg
2.14M
Vol Ratio
0.00x
Liquidity
LIQUID

Earnings Momentum

Q4'24+74%
$0.47
Q1'25+358%
$0.55
Q2'25-16%
$0.65
Q3'25+75%
$0.70
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+51.19%
5 Years:+18.63%
3 Years:+12.93%
TTM:+9.93%

Compounded Profit Growth

10 Years:—
5 Years:+51.35%
3 Years:+70.59%
TTM:+51.92%

Stock Price CAGR

10 Years:+28.32%
5 Years:+14.59%
3 Years:+37.15%
1 Year:+13.88%

Return on Equity

10Y Avg:20.6%
5Y Avg:17.3%
3Y Avg:22.5%
Last Year:31.4%

Key Metrics

Market Cap$11.8B
Gross Margin—
Net Margin33.7%
Piotroski F-Score7/9

More EXEL Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

EXEL vs RVMDRVMDINCYGMABIBRX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 57 meansEXEL outperformed 57% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.63 means 37% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 7/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 8/10 with WARM status.

Frequently Asked Questions

Is EXEL in an uptrend right now?

EXEL has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is EXEL overbought or oversold?

EXEL's RSI (14) is 53. The stock is in neutral territory, neither overbought nor oversold.

Is EXEL outperforming the market?

EXEL has a Relative Strength (RS) Rating of 57 out of 99. EXEL is performing about average compared to the market.

Where is EXEL in its 52-week range?

EXEL is trading at $44.06, which is 89% of its 52-week high ($49.62) and 68% above its 52-week low ($32.38).

How volatile is EXEL?

EXEL has a Beta of 0.63 and 52-week volatility of 43%. It's less volatile than the S&P 500 - generally more stable.